Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.

Mazzarino M, Colpaert T, Deventer K, Van Eenoo P

The Analyst27 Jul 2026

PMID42328738DOI10.1039/d6an00455ePepBankPUB-42328738

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study21

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone21

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01LabNot a test of BPC-157 aloneIn vitro (cell-free)Other
In dried blood spots, serum and plasma, BPC‑157 was stable (variation lower than 15%) for at least two months at -20 °C.
In plain wordsIn lab tests, BPC‑157 stayed stable in stored blood samples for at least two months when frozen at -20 °C.
Peptide
BPC-157
Outcome
No significant changeStability at -20 °C in blood matrices
Study
n: not reported in source
Dried blood spots, serum and plasma
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Variation
< 15%
-20 °C, two months
Source sentences
Summary
Stability studies showed that all compounds were stable (variation lower than 15%) for at least two months at -20 °C in all the blood matrices considered.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we report a fast, streamlined, and harmonized analytical workflow to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum, and plasma.
In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking BPC-157.
Report a problemFND-4232873807
02LabNot a test of BPC-157 aloneIn vitro (cell-free)Other
In serum, BPC‑157 degraded completely within one week at 4 and 22 °C.
In plain wordsIn lab tests, BPC‑157 broke down completely in serum within one week at 4 or 22 °C.
Peptide
BPC-157
Outcome
DecreaseStability at 4 and 22 °C in serum and plasma
Study
n: not reported in source
Dried blood spots, serum and plasma
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
whereas BPC-157, TB500, vasopressin, lypressin, and terlipressin showed complete degradation only in serum
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we report a fast, streamlined, and harmonized analytical workflow to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum, and plasma.
In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking BPC-157.
Report a problemFND-4232873808
03LabNot a test of BPC-157 aloneIn vitro (cell-free)Other
In dried blood matrices, BPC‑157 remained detectable throughout the whole study period.
In plain wordsIn lab tests, BPC‑157 stayed detectable in dried blood samples for the whole study, so they may be stored without refrigeration.
Peptide
BPC-157
Outcome
No significant changeDetectability in dried matrices
Study
n: not reported in source
Dried blood spots, serum and plasma
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
In contrast, in dried matrices all compounds remained detectable throughout the entire duration of the study, indicating that samples can be transported and stored under non-refrigerated conditions, thereby reducing costs.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we report a fast, streamlined, and harmonized analytical workflow to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum, and plasma.
In this study, BPC-157 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking BPC-157.
Report a problemFND-4232873809
04LabNot a test of Kisspeptin-10 aloneIn vitro (cell-free)Other
In dried blood spots, serum and plasma, kisspeptin‑10 was stable (variation lower than 15%) for at least two months at -20 °C.
In plain wordsIn lab tests, kisspeptin‑10 stayed stable in stored blood samples for at least two months when frozen at -20 °C.
Peptide
Kisspeptin-10
Outcome
No significant changeStability at -20 °C in blood matrices
Study
n: not reported in source
Dried blood spots, serum and plasma
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Variation
< 15%
-20 °C, two months
Source sentences
Summary
Stability studies showed that all compounds were stable (variation lower than 15%) for at least two months at -20 °C in all the blood matrices considered.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we report a fast, streamlined, and harmonized analytical workflow to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum, and plasma.
In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.
Report a problemFND-4232873810
05LabNot a test of Kisspeptin-10 aloneIn vitro (cell-free)Other
In serum and plasma, kisspeptin‑10 was extensively degraded after one week at 4 and 22 °C.
In plain wordsIn lab tests, kisspeptin‑10 was largely broken down in serum and plasma after one week at 4 or 22 °C.
Peptide
Kisspeptin-10
Outcome
DecreaseStability at 4 and 22 °C in serum and plasma
Study
n: not reported in source
Dried blood spots, serum and plasma
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
At 4 and 22 °C, alexamorelin, AOD9604, buserelin, hGH 176-191, kisspeptin-10 and LHRH were extensively degraded after one week in serum and plasma
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we report a fast, streamlined, and harmonized analytical workflow to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum, and plasma.
In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.
Report a problemFND-4232873811
06LabNot a test of Kisspeptin-10 aloneIn vitro (cell-free)Other
In dried blood matrices, kisspeptin‑10 remained detectable throughout the whole study period.
In plain wordsIn lab tests, kisspeptin‑10 stayed detectable in dried blood samples for the whole study, so they may be stored without refrigeration.
Peptide
Kisspeptin-10
Outcome
No significant changeDetectability in dried matrices
Study
n: not reported in source
Dried blood spots, serum and plasma
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
In contrast, in dried matrices all compounds remained detectable throughout the entire duration of the study, indicating that samples can be transported and stored under non-refrigerated conditions, thereby reducing costs.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we report a fast, streamlined, and harmonized analytical workflow to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum, and plasma.
In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.
Report a problemFND-4232873812
07LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Other
In blood-matrix assays, the multi-analyte method including ibutamoren showed no interference at analyte retention times.
In plain wordsIn lab tests, the method including ibutamoren showed no interference at analyte retention times.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableAnalytical selectivity
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
selectivity (no interferences were detected at the retention times of the analytes)
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we report a fast, streamlined, and harmonized analytical workflow to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum, and plasma.
Summary · context
Detection was performed using liquid chromatography coupled with high-resolution mass spectrometry.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-4232873813
08LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Other
In blood-matrix assays, detection limits across analytes including ibutamoren were 0.05-1.25 ng mL⁻¹.
In plain wordsIn lab tests, detection limits across analytes including ibutamoren were 0.05-1.25 ng mL⁻¹.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableDetection limits
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Detection limit
0.05 to 1.25 ng mL⁻¹
all analytes
Source sentences
Summary
detection limits (0.05-1.25 ng mL^-1),
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we report a fast, streamlined, and harmonized analytical workflow to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum, and plasma.
Summary · context
Detection was performed using liquid chromatography coupled with high-resolution mass spectrometry.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-4232873814
09LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Other
In blood-matrix assays, the multi-analyte method including ibutamoren showed no signals in negative samples after positive samples.
In plain wordsIn lab tests, the method including ibutamoren showed no signals in negative samples after positive samples.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableCarry-over
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
carry-over (no signals in the negative sample injected after the positive sample),
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we report a fast, streamlined, and harmonized analytical workflow to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum, and plasma.
Summary · context
Detection was performed using liquid chromatography coupled with high-resolution mass spectrometry.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-4232873815
10LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Other
In blood-matrix assays, matrix effects across analytes including ibutamoren ranged from 5-33%.
In plain wordsIn lab tests, matrix effects across analytes including ibutamoren ranged from 5-33%.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableMatrix effect
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Matrix effect
5 to 33%
all analytes
Source sentences
Summary
matrix effect (5-33%)
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we report a fast, streamlined, and harmonized analytical workflow to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum, and plasma.
Summary · context
Detection was performed using liquid chromatography coupled with high-resolution mass spectrometry.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-4232873816
11LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Other
In blood-matrix assays, extraction yields across analytes including ibutamoren ranged from 15-80%.
In plain wordsIn lab tests, extraction yields across analytes including ibutamoren ranged from 15-80%.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableExtraction yield
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Extraction yield
15 to 80%
all analytes
Source sentences
Summary
extraction yield (15-80%)
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we report a fast, streamlined, and harmonized analytical workflow to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum, and plasma.
Summary · context
Detection was performed using liquid chromatography coupled with high-resolution mass spectrometry.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-4232873817
12LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Other
In lab extracts, target analytes including ibutamoren remained stable for at least 72 h at 10 °C.
In plain wordsIn lab tests, extracted analytes including ibutamoren remained stable for at least 72 h at 10 °C.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableExtract stability
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
extract stability (the target analytes were stable for at least 72 h in the autosampler at 10 °C).
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we report a fast, streamlined, and harmonized analytical workflow to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum, and plasma.
Summary · context
Detection was performed using liquid chromatography coupled with high-resolution mass spectrometry.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-4232873818
13LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Other
In sample analysis, the method successfully detected sub-ng levels of ibutamoren.
In plain wordsIn lab tests, the method successfully detected sub-ng levels of ibutamoren.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableDetection in samples
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
The method was successfully applied to samples containing sub-ng levels of ibutamoren,
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we report a fast, streamlined, and harmonized analytical workflow to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum, and plasma.
Summary · context
Detection was performed using liquid chromatography coupled with high-resolution mass spectrometry.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-4232873819
14LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Other
In blood matrices, all compounds including ibutamoren remained stable for at least two months at -20 °C, with variation lower than 15%.
In plain wordsIn lab tests, all compounds including ibutamoren remained stable for at least two months at -20 °C.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableFrozen blood-matrix stability
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
Stability studies showed that all compounds were stable (variation lower than 15%) for at least two months at -20 °C in all the blood matrices considered.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we report a fast, streamlined, and harmonized analytical workflow to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum, and plasma.
Summary · context
Detection was performed using liquid chromatography coupled with high-resolution mass spectrometry.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-4232873820
15LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Other
In dried matrices, all compounds including ibutamoren remained detectable throughout the study.
In plain wordsIn lab tests, all compounds including ibutamoren remained detectable in dried matrices throughout the study.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableDetectability in dried matrices
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
In contrast, in dried matrices all compounds remained detectable throughout the entire duration of the study,
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we report a fast, streamlined, and harmonized analytical workflow to detect 54 prohibited peptidic and non-peptidic compounds in dried blood spots, serum, and plasma.
Summary · context
Detection was performed using liquid chromatography coupled with high-resolution mass spectrometry.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-4232873821
16LabNot a test of AOD-9604 aloneOther designOther
AOD9604 was stable (variation lower than 15%) for at least two months at -20 °C in all blood matrices tested.
In plain wordsIn lab tests, AOD9604 stayed stable in blood samples stored frozen for at least two months.
Peptide
AOD-9604
Outcome
No significant changeStability at -20 °C in blood matrices
Study
n: not reported in source
dried blood spots, serum and plasma
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
Stability studies showed that all compounds were stable (variation lower than 15%) for at least two months at -20 °C in all the blood matrices considered.
In this study, AOD-9604 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking AOD-9604.
Report a problemFND-4232873801
17LabNot a test of TB-500 aloneOther designOther
TB500 was stable (variation lower than 15%) for at least two months at -20 °C in all blood matrices tested.
In plain wordsIn lab tests, TB500 stayed stable in blood samples stored frozen for at least two months.
Peptide
TB-500
Outcome
No significant changeStability at -20 °C in blood matrices
Study
n: not reported in source
dried blood spots, serum and plasma
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
Stability studies showed that all compounds were stable (variation lower than 15%) for at least two months at -20 °C in all the blood matrices considered.
In this study, TB-500 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking TB-500.
Report a problemFND-4232873802
18LabNot a test of AOD-9604 aloneOther designOther
AOD9604 was extensively degraded after one week at 4 and 22 °C in serum and plasma.
In plain wordsIn lab tests, AOD9604 broke down a lot within one week in serum and plasma kept at 4 or 22 °C.
Peptide
AOD-9604
Outcome
DecreaseStability at 4 and 22 °C in serum and plasma
Study
n: not reported in source
dried blood spots, serum and plasma
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
At 4 and 22 °C, alexamorelin, AOD9604, buserelin, hGH 176-191, kisspeptin-10 and LHRH were extensively degraded after one week in serum and plasma, whereas BPC-157, TB500, vasopressin, lypressin, and terlipressin showed complete degradation only in serum.
In this study, AOD-9604 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking AOD-9604.
Report a problemFND-4232873803
19LabNot a test of TB-500 aloneOther designOther
TB500 showed complete degradation after one week at 4 and 22 °C in serum only.
In plain wordsIn lab tests, TB500 broke down completely within one week in serum kept at 4 or 22 °C.
Peptide
TB-500
Outcome
DecreaseStability at 4 and 22 °C in serum
Study
n: not reported in source
dried blood spots, serum and plasma
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
At 4 and 22 °C, alexamorelin, AOD9604, buserelin, hGH 176-191, kisspeptin-10 and LHRH were extensively degraded after one week in serum and plasma, whereas BPC-157, TB500, vasopressin, lypressin, and terlipressin showed complete degradation only in serum.
In this study, TB-500 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking TB-500.
Report a problemFND-4232873804
20LabNot a test of AOD-9604 aloneOther designOther
AOD9604 remained detectable in dried matrices throughout the whole study.
In plain wordsIn lab tests, AOD9604 stayed detectable in dried blood samples for the whole study.
Peptide
AOD-9604
Outcome
No significant changeStability in dried matrices
Study
n: not reported in source
dried blood spots, serum and plasma
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
In contrast, in dried matrices all compounds remained detectable throughout the entire duration of the study, indicating that samples can be transported and stored under non-refrigerated conditions, thereby reducing costs.
In this study, AOD-9604 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking AOD-9604.
Report a problemFND-4232873805
21LabNot a test of TB-500 aloneOther designOther
TB500 remained detectable in dried matrices throughout the whole study.
In plain wordsIn lab tests, TB500 stayed detectable in dried blood samples for the whole study.
Peptide
TB-500
Outcome
No significant changeStability in dried matrices
Study
n: not reported in source
dried blood spots, serum and plasma
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
In contrast, in dried matrices all compounds remained detectable throughout the entire duration of the study, indicating that samples can be transported and stored under non-refrigerated conditions, thereby reducing costs.
In this study, TB-500 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking TB-500.
Report a problemFND-4232873806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 32 to 49Current
28 Oct 2026, 02:04 UTC
The same notice was added 18 times, first on 14 Oct 2026, 05:01 UTC. The status did not change between them.
Study results updated
Version 31
14 Oct 2026, 01:46 UTC
Study data updated · source update from Europe PMC
Versions 7 to 30
13 Oct 2026, 21:46 UTC
The same notice was added 24 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Versions 2 to 6
9 Oct 2026, 03:04 UTC
The same notice was added 5 times, first on 9 Oct 2026, 02:56 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.